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Introduction
Sudden cardiac death remains as an important public health problem, even in
industrialised countries, despite the considerable improvement in emergency
medical services and the introduction of new therapeutic strategies. Sudden
cardiac death (SCD) is responsible for 50% of the mortality from cardiovascu-
lar disease [1]. In many cases, SCD may be the first manifestation of coronary
artery disease. It is the most common cause of death due to ischaemic heart
disease among the adult population under 65 years of age, and survival rates
after out-of-hospital cardiac arrest remain low. It has been shown in clinical
trials that, compared to the administration of antiarrhythmic drugs,
implantable cardioverter defibrillators (ICD) significantly reduce mortality
due to SCD. This treatment option has added a new dimension to the preven-
tion and management of SCD. Besides antiarrhythmic drugs and ICDs, there
are other drugs that have an indirect but nonetheless important role in pre-
venting SCD. Although these medications do not have a direct electrophysio-
logic action, they prevent SCD by affecting basic neurohumoral, ischaemic,
biochemical, and fibrotic mechanisms that may cause ventricular tach-
yarrhythmias. Aldosterone antagonists are an example of non-antiarrhythmic
drugs that have been shown to reduce the incidence of SCD in clinical trials.
Cardiovascular Effects of Aldosterone
Following its discovery in the early 1950s, the endocrine actions of aldos-
terone have been extensively studied and documented [2–5]. Aldosterone’s
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main endocrine function is the regulation of sodium and potassium, and
volume homeostasis. The activity of the hormone is mediated through sodi-
um reabsorption and potassium excretion in the distal renal tubules and col-
lecting ducts. Its release from the adrenal cortex is stimulated by increased
levels of serum potassium, angiotensin II, adrenocorticotropic hormone
(ACTH), and by sodium depletion [6–8]. Aldosterone regulates extracellular
volume and electrolyte balance via mineralocorticoid receptors on renal
tubular epithelial cells.
In addition to renal tubular epithelial cells, mineralocorticoid (MR)
receptors are present in various non-renal locations [9], mainly, heart [10,
11], brain tissue [12], and the vasculature [13]. This finding suggests that
aldosterone has local effects at different tissue levels. In animal studies,
aldosterone biosynthesis was also shown in myocardium [11], brain [12] and
vascular smooth muscle cells [14]. Aldosterone synthesis at extra-adrenal
sites seems to be regulated by the same factors that regulate adrenal synthe-
sis, and many of the negative effects of aldosterone are mediated by MR
receptors in these non-renal sites. For example, increased local production of
aldosterone and angiotensin converting enzyme (ACE) have been detected in
the ventricles of patients with heart failure. It has been shown that aldos-
terone contributes to cardiovascular toxicity in humans independent of the
effects of angiotensin II, and a correlation exists between aldosterone con-
centration and cardiovascular morbidity and mortality. In the Cooperative
North Scandinavian Enalapril Survival Study (CONSENSUS), significantly
greater mortality at 6 months was shown in patients who had baseline
aldosterone concentration above the median values [15].
In patients with heart failure, overproduction of aldosterone leads to an
inappropriate increase in sodium and water retention. This fluid and sodium
retention produces a volume overload that further impairs the ability of the
heart to pump adequate amount of blood to peripheral tissues. With the
reduction of forward blood flow, a generalised systemic vasoconstriction
occurs that impairs renal blood flow. Eventually, a vicious circle is formed in
which the release of angiotensin II from the kidneys leads to a further rise in
aldosterone and volume overload.
Aldosterone increases the risk of ventricular arrhythmias by increasing
renal potassium and magnesium excretion [16]. Because of the negative
effect of this electrolyte imbalance, aldosterone increases the risk of SCD in
patients with heart failure and in post-myocardial-infarction (MI) patients.
In patients with congestive heart failure, the kaliuretic and magnesiuretic
effects of aldosterone can be reverted by aldosterone receptor antagonists,
which may explain the preventive effects of these drugs on SCD. Aldosterone
has also been demonstrated to have proarrhythmogenic effects on rabbit
cardiomyocytes by increasing sodium influx and Na/K pump activity [17].
416 L. Sahiner, A. Oto
An animal study showed that aldosterone exposure increased calcium cur-
rent in adult rat cardiomyocytes, an effect that was inhibited following aldos-
terone blockade by spironolactone [18].
It has been shown in various animal models and clinical studies that
aldosterone causes cardiovascular injury, independent of its effects on blood
pressure – the so-called mechanical effects of aldosterone. Aldosterone caus-
es vascular inflammation and fibrosis in animal models. The mechanisms
through which aldosterone causes cardiac and vascular fibrosis have been
investigated in many studies. Aldosterone increases vascular angiotensin
(AT)1 receptor binding [19]. It also increases AT1 receptor density and
mRNA accumulation in rat heart [20]. Thus, aldosterone may, at least in part,
exert its adverse effects on cardiac remodelling by potentiating the effects of
angiotensin II. Moreover, aldosterone has been shown to have a direct pro-
fibrotic action by increasing collagen production by cardiac fibroblasts [21,
22]. It also increases plasminogen activator inhibitor-1 (PAI-1) expression,
which promotes fibrosis [23, 24]. In an animal study in normotensive rats,
aldosterone infusion for 24 h led to increased cardiomyocyte apoptosis [25].
Since necrotic myocytes serve as stimuli for fibrosis in myocardium [26],
increased apoptosis and myocardial necrosis may be another mechanism to
explain aldosterone-mediated cardiac fibrosis.
Propeptide of type III collagen (PIIINP) is a serum marker of collagen
synthesis. In the Randomised Aldactone Evaluation Study (RALES), serum
PIIINP levels were significantly reduced in a group of patients treated with
spironolactone [27]. In a study by Modena, 46 post-MI patients were ran-
domised to spironolactone or to placebo. After a 1-year follow-up, serum PII-
INP levels were found to be lower in the treatment arm [28]. These data sug-
gest that aldosterone exerts an adverse remodelling effect on myocardium
and promotes cardiac fibrosis. Increased myocardial fibrosis may act as a
substrate for the genesis of life-threatening ventricular arrhythmias.
Aldosterone has also been shown to have proatherogenic actions and it
promotes endothelial dysfunction [29]. Possible mechanisms that may be
involved in aldosterone’s effect on endothelial function include aldosterone-
induced reduction of NO levels and a reduction in the generation of oxygen
free radicals [30, 31]. Patients with heart failure who were treated with
spironolactone for 1 month had an increased endothelium-dependent fore-
arm blood-flow response to acetylcholine [32]. Aldosterone induces vascular
inflammation and fibrinoid necrosis of the small arteries and arterioles,
leading to a reperative fibrotic process. An inverse relation between aldos-
terone and large-artery compliance in late-stage heart failure patients has
also been suggested [33]. Together with its hypertensive effects, aldosterone
increases the occurrence of ischaemic events by promoting endothelial dys-
function, perivascular fibrosis, and a decrease in arterial compliance. This
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constitutes a suitable background for the progression of heart failure and the
occurrence of arrhythmic SCD.
Experimental studies suggest that aldosterone has autonomic effects,
independent of the actions of angiotensin II. Aldosterone blunts the barore-
ceptor heart-rate response to noradrenaline infusion and increases sympa-
thetic nervous system activity [34]. It modulates parasympathetic tone and
results in reduced heart rate variability (HRV) parameters. Reduced HRV is
associated with increased mortality and a higher incidence of SCD in heart
failure [35]. Aldosterone has also been shown to block extraneuronal nora-
drenaline uptake [36]. All of these actions of aldosterone can predispose to
arrhythmias and SCD.
In a study conducted in rats, aldosterone blockade by canrenone (active
metabolite of spironolactone) was found to attenuate left ventricular (LV)
remodelling, improve LV systolic and diastolic function, reduce interstitial
and perivascular fibrosis, decrease myocardial norepinephrine content, and
increase the ventricular fibrillation threshold [37]. A study by Ramires et al.
showed that addition of spironolactone to standard therapy in patients with
congestive heart failure due to idiopathic or ischaemic dilated cardiomyopa-
thy reduces the frequency of ventricular premature complexes and episodes
of non-sustained ventricular tachycardia [38]. Aldosterone blockade has also
been shown to reduce vascular collagen turnover, improve HRV, and reduce
heart rate, especially in the early morning hours [35]. The latter finding is
particularly noteworthy as it suggests that blocking the action of aldosterone
reduces the incidence of ischaemia in the early-morning, when sudden death
is 2.5 times more common in patients with heart failure. Addition of spiron-
dactone to conventional treatment decreases QT dispersion [39] and has
positive effects on HRV [40].
The ‘Aldosterone Escape’ Phenomenon
Despite the lowering of angiotensin II activity, ACE inhibitors completely
block aldosterone production. In fact, a progressive rise in aldosterone levels
under ACE inhibitor therapy has been demonstrated in clinical studies. This
finding, termed ‘aldosterone escape,’ may be explained by ATII production
independent of ACE activity (so-called angiotensin escape), ACE production
that is not inhibited by ACE inhibitors, and ATII-independent aldosterone
production. MacFadyen and colleagues reported that in patients with symp-
tomatic heart failure who were on ACE inhibitor therapy aldosterone sup-
pression failed in 38% of cases [41]. In the Randomised Evaluation of
Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study, aldos-
terone levels were significantly lower after 17 weeks in both treatment arms
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(candesartan and enalapril); however, levels returned almost to baseline in
all three groups by the 43rd week [42]. In another study, conducted in a
smaller sample of heart failure patients, 11 of 34 patients had elevated serum
aldosterone levels in spite of complete ACE inhibition [43]. These data,
together with knowledge of the correlation between serum aldosterone levels
and mortality in heart failure patients, constitute the rationale for more spe-
cific blockade of aldosterone action in addition to ACE inhibition in patients
with heart failure.
Sudden Cardiac Death and Aldosterone Receptor Antagonists: What We
Have Learned from Recent Trials
Two important landmark studies have shown the clinical benefits of aldos-
terone receptor antagonists, RALES [44] (Randomised Aldactone Evaluation
Study) and EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart
Failure Efficacy and Survival Study) [45].
RALES was a randomised double-blind study that enrolled 1663 patients
with severe heart failure, a LV ejection fraction below 35%, and who were
being treated with ACE inhibitor, digitalis, and diuretics. Patients were ran-
domly assigned to receive 25 mg spironolactone or placebo to assess the
primary end-point of death from all causes. The trial was stopped early,
after a mean follow-up of 24 months, because of the significant beneficial
effect of spironolactone. There was a 30% reduction in the risk of death
among patients in the spironolactone group. Importantly, spironolactone
reduced the risk of death from progressive heart failure and SCD. The
authors suggested that the preventive effect of spironolactone on SCD was
related to decreased potassium loss and increased myocardial uptake of
norepinephrine in response to the drug. The potential of spironolactone in
preventing myocardial fibrosis was also suggested to have a role in reducing
the risk of SCD, as myocardial fibrosis is well-known to predispose patients
to reentry ventricular arrhythmias. One of the criticisms of the RALES
study was that only 11% of the patients were on beta-blocker therapy. Since
some of the beneficial effects of beta-blockers and spironolactone are pro-
duced by similar mechanisms, it is unclear whether spironolactone would
still have a beneficial effect if the majority of patients were also on beta-
blocker therapy. A substudy of RALES, published later, implicated a poten-
tial link between the antifibrotic effects of spironolactone and decreased
mortality [27]. In this study, serum levels of PIIINP, which is a marker of
collagen turnover, were significantly reduced by spironolactone and this
predicted decreased mortality.
Eplerenone is a new, competitive antagonist of aldosterone that has a
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higher degree of selectivity for the mineralocorticoid receptor. EPHESUS
was conducted as a double-blind, placebo-controlled study to evaluate the
effect of eplerenone on mortality and morbidity among post-MI patients
with additional complications of LV dysfunction and heart failure. The 6632
patients participating in the study were randomly distributed to eplerenone
and placebo arms in addition to optimal medical therapy. After 16 months
of follow-up, eplerenone was found to reduce risk of death from any cause by
15%. It also reduced cardiovascular deaths and hospitalisations due to car-
diovascular events. Interestingly, eplerenone decreased the rate of SCD by
21%. In contrast to RALES, 75% of the patients in EPHESUS were on beta-
blocker therapy.
In EPHESUS, a large part of the reduction in cardiovascular mortality
was due to a 21% reduction in the rate of SCD. The authors postulated that
this important beneficial effect was due, in part, to a positive effect of aldos-
terone on electrolyte (especially potassium and magnesium) balance. Other
proposed mechanisms were reduction of coronary vascular inflammation
and interstitial fibrosis, reduction of oxidative stress, improvement in
endothelial function, attenuation of platelet aggregation, improvement in
ventricular remodelling, reduction of sympathetic tonus, and improvement
in HRV and norepinephrine uptake.
Conclusions
Based on these data, we can conclude that although aldosterone antagonists
are non-antiarrhythmic drugs, they have a significant preventive effect on
SCD. The available data have focused particularly on the patients with low
ejection fraction and congestive heart failure. New studies are needed to
expand the indications to use aldosterone antagonists to prevent SCD.
Potential mechanisms by which these drugs prevent SCD include prevention
of aldosterone-induced cardiac and arterial fibrosis, improvement in arterial
compliance, reduction of the adverse effects of aldosterone on cardiac
remodelling, improvement of endothelial function and NO activity, improve-
ment in the autonomic nervous system function via a reduction in sympa-
thetic nervous system tonus, improvement in HRV and baroreflex sensitivity,
and an increase in myocardial norepinephrine uptake By decreasing urinary
excretion of potassium and magnesium, aldosterone antagonists also aid in
protecting against life-threatening ventricular arryhthmias.
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